Piper Sandler lowers Arbor Realty Trust stock price target on credit issues
Silo Pharma Inc. (SILO) announced it has selected the Alphaledger/Simplify Target 12% Distribution Fund as part of its real-world asset investment strategy on the Solana blockchain. The biopharmaceutical company said the allocation aligns with its treasury diversification objectives.
The Alphaledger T12 Fund operates as a digital investment vehicle providing access to tokenized real-world assets on public blockchains. The fund utilizes a portfolio of fixed income, credit, and option strategies designed to generate monthly income while operating on Solana’s blockchain infrastructure.
"We view this investment not only as a treasury diversification tool, but as an important step toward embracing decentralized financial infrastructure," said Eric Weisblum, CEO of Silo Pharma . The company stated the fund offers exposure to yield-generating tokenized assets while seeking to reduce portfolio volatility.
Manish Dutta, Co-Founder and CEO of Alphaledger, said Silo’s adoption reflects how institutional participants are integrating tokenized real-world assets into regulated investment frameworks. Alphaledger was founded in 2019 by Dutta, a former PIMCO executive, and Chris Wade.
The Alphaledger T12 Fund is managed by Alphaledger Investment Management LLC, a subsidiary of Alpha Ledger Technologies Inc. The parent company’s affiliates include an SEC registered transfer agent and a FINRA-registered broker dealer.
Silo Pharma describes itself as a developmental-stage biopharmaceutical and cryptocurrency treasury company focused on stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. The company’s portfolio includes programs for PTSD, fibromyalgia, Alzheimer’s disease, and multiple sclerosis.